Percutaneous coronary intervention unstable angina / non-ST elevation myocardial infarction (UA/NSTEMI)
Jump to navigation
Jump to search
Percutaneous Coronary Intervention Guidelines Microchapters |
PCI Approaches: |
---|
CAD Revascularization: |
Pre-procedural Considerations: |
Procedural Considerations: |
|
|
|
|
|
|
|
|
|
Post-Procedural Considerations: |
Quality and Performance Considerations: |
Percutaneous coronary intervention unstable angina / non-ST elevation myocardial infarction (UA/NSTEMI) On the Web |
American Roentgen Ray Society Images of Percutaneous coronary intervention unstable angina / non-ST elevation myocardial infarction (UA/NSTEMI) |
Directions to Hospitals Treating Percutaneous Coronary Intervention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
2011 ACCF/AHA/SCAI Guidelines for Percutaneous Coronary Intervention (DO NOT EDIT)[1]
Intravenous Antiplatelet Therapy in Unstable Angina/Non-ST Elevation Myocardial Infarction (UA/NSTEMI) (DO NOT EDIT)[1]
Class I |
"1. In UA/NSTEMI patients with high-risk features (e.g., elevated troponin level) not treated with bivalirudin and not adequately pre-treated with clopidogrel, it is useful at the time of PCI to administer a GP IIb/IIIa inhibitor (abciximab,double-bolus eptifibatide, or high-bolus dose tirofiban) in patients treated with unfractionated heparin therapy (UFH).[2][3][4][5][6][7] (Level of Evidence: A)" |
Class IIa |
"1. In UA/NSTEMI patients with high-risk features (e.g., elevated troponin level) treated with unfractionated heparin therapy (UFH) and adequately pretreated with clopidogrel, it is reasonable at the time of PCI to administer a GP IIb/IIIa inhibitor (abciximab,double-bolus eptifibatide, or high-bolus dose tirofiban).[5][8] (Level of Evidence: B)" |
References
- ↑ 1.0 1.1 Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH (2011). "2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions" (PDF). Journal of the American College of Cardiology. 58 (24): 2550–83. doi:10.1016/j.jacc.2011.08.006. PMID 22070837. Retrieved 2011-12-08. Text "PDF" ignored (help); Unknown parameter
|month=
ignored (help) - ↑ "Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators". The New England Journal of Medicine. 336 (24): 1689–96. 1997. doi:10.1056/NEJM199706123362401. PMID 9182212. Retrieved 2011-12-15. Unknown parameter
|month=
ignored (help) - ↑ Boersma E, Akkerhuis KM, Théroux P, Califf RM, Topol EJ, Simoons ML (1999). "Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention". Circulation. 100 (20): 2045–8. PMID 10562258. Retrieved 2011-12-15. Unknown parameter
|month=
ignored (help) - ↑ Hamm CW, Heeschen C, Goldmann B, Vahanian A, Adgey J, Miguel CM, Rutsch W, Berger J, Kootstra J, Simoons ML (1999). "Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators". The New England Journal of Medicine. 340 (21): 1623–9. doi:10.1056/NEJM199905273402103. PMID 10341274. Retrieved 2011-12-15. Unknown parameter
|month=
ignored (help) - ↑ 5.0 5.1 Sosnowski C (2006). "[Commentary to the article: Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006; 295: 1531-8]". Kardiologia Polska (in Polish). 64 (8): 913–6, discussion 917–8. PMID 16981067. Retrieved 2011-12-15. Unknown parameter
|month=
ignored (help) - ↑ Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Heeschen C, Hamm CW, Moliterno DJ, Califf RM, White HD, Kleiman NS, Théroux P, Topol EJ (2001). "Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes". Circulation. 104 (23): 2767–71. PMID 11733392. Retrieved 2011-12-15. Unknown parameter
|month=
ignored (help) - ↑ "Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation". The New England Journal of Medicine. 330 (14): 956–61. 1994. doi:10.1056/NEJM199404073301402. PMID 8121459. Retrieved 2011-12-15. Unknown parameter
|month=
ignored (help) - ↑ Valgimigli M, Percoco G, Barbieri D, Ferrari F, Guardigli G, Parrinello G, Soukhomovskaia O, Ferrari R (2004). "The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial". Journal of the American College of Cardiology. 44 (1): 14–9. doi:10.1016/j.jacc.2004.03.042. PMID 15234398. Retrieved 2011-12-15. Unknown parameter
|month=
ignored (help)